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Clinical decision models are intended to guide the choices of 
individual clinicians; policy models are intended to guide 
the choices of persons and organizations that affect the 
aggregate allocations of resources to health care problems. 
Although it is difficult to identify any single policymaker in 
the United States who can alter the aggregate effect of the 
millions (or billions) of individual clinical decisions, there 
are many potential users of policy models: payers, provid- 
ers, state and local health departments, the National Insti- 
tutes of Health, professional organizations, hospitals and 
producers of medical devices, among others. 
Policy models deal with populations of individuals, may 
he static or dynamic and may he descriptive or prescriptive. 
Two types of policy models that have been applied to 
cardiovascular disease with a focus on coronary artery 
bypass surgery are discussed: 1) economic evaluation mod- 
els, specifically cost-effectiveness, cost utility and cost- 
benefit analyses; and 2) population simulation models. 
Cost-effectiveness models are preferable for reasons that 
are discussed. 
(J Am Co11 Cardiol1989;14:38AA3A) 
Policy Models and Cardiovascular Disease 
If a “clinical decision model” is intended to guide the 
choices of individual clinicians and their patients, then a 
“policy model” in health care is intended to guide the 
choices of persons and organizations that, by virtue of 
regulatory authority, direct control of resources or the 
power to influence the actions of others, affect the aggregate 
allocations of resources to a health care problem. In the 
pluralistic and decentralized U.S. health care system, it is 
difficult to identify any single policy decision maker who, by 
any discrete action, can purposefully alter the aggregate 
effect of the millions (or billions) of individual clinical 
decisions made annually in the care of patients with, or at 
risk of developing, cardiovascular disease. Nevertheless, 
one can identify many potential users of policy models even 
if their degree of control over the ultimate allocation of 
resources is limited. 
the decisions of individual clinical decisions. State and local 
health departments can use policy models to set priorities 
and design categorical programs. The National Institutes of 
Health can use policy models to set priorities for research, 
and manpower and capital policies can be influenced by the 
predictions or conclusions from disease-specific policy mod- 
els. 
Potential users of policy models. In the public sector, 
payers such as Medicare and Medicaid can influence re- 
source use by using payment rates as levers. Direct provid- 
ers of health care such as the Veterans Administration are 
potential users, but their “policies” must still be reflected in 
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In the private sector, professional organizations such as 
the American Medical Association, the American College of 
Physicians or the American College of Cardiology can use 
insights obtained from policy models to influence clinical 
practice through the power of persuasion. Hospitals, health 
maintenance organizations and other providers, too, can use 
policy models to guide resource allocations in the manage- 
ment of a disease such as coronary heart disease, and the 
trend toward managed care contracts increases incentives of 
provider organizations to optimize care of patient popula- 
tions within resource constraints. Finally, producers of 
medical devices and pharmaceutical agents can use policy 
models in strategic planning and marketing to determine 
what products are likely to be most profitable and to per- 
suade purchasers that their products are cost-effective. The 
implication of this multiplicity of “policymakers” in the 
health care sector is that policy modelers need to be sensi- 
tive to the needs of potential users and to orient the models 
to the decision perspectives of persons and organizations 
that are in the best position to use them. I will return to this 
aspect of dissemination and implementation of policy models 
later. 
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Characteristics of policy models, Policy models in health 
care have populations of individuals as their substrate. 
These populations may be narrowly defined as those 
facing specific diagnostic or therapeutic choices, such as 
45 to 64 year old men with mild chest pain or 35 to 44 
year old women with diastolic blood pressure in the range 
of 90 to 104 mm Hg. They may be broadly defined to 
encompass the population of an insurance pool, health 
maintenance organization (HMO), state or nation, and 
stratified according to demographic, risk factor and clin- 
ical variables. 
Policy models may be either static or dynamic. A static 
model focuses on a decision at a single point in time. A 
dynamic model concerns the interplay of changing factors as 
they evolve over time. 
Finally, policy models may be descriptive or prescriptive. 
A descriptive model is intended to describe, or predict, the 
consequence of a set of demographic, epidemiologic, clinical 
or economic assumptions. A prescriptive model goes a step 
further and evaluates which of several decision options 
optimizes a specified objective, such as to achieve the 
maximal gain in life expectancy subject to a resource con- 
straint . 
Obviously, the distinctions between narrow and broad 
target populations, static and dynamic and descriptive and 
prescriptive are idealizations; most policy models contain 
elements of both ends of each spectrum. The taxonomy 
is useful, however, in helping to define the purposes of 
a model and evaluate whether it is doing what it purports 
to do. 
I will focus on two types of policy models that have been 
applied to cardiovascular disease. Not coincidentally, these 
are the types with which I have worked most closely. There 
are other types of policy models, but rather than attempt a 
comprehensive review, I have chosen to focus on these two, 
which I know best. They are 1) economic evaluation models, 
specifically, cost-effectiveness, cost-utility and cost-benefit 
analyses; and 2) population simulation models. In terms of 
the taxonomy, economic evaluation models are generally 
prescriptive, static and directed at a narrowly defined target 
population, whereas population simulation models are gen- 
erally descriptive, dynamic and applied to a general popula- 
tion. This is not to say that population simulation models 
cannot be used prescriptively or that cost-effectiveness 
models do not have dynamic features, but these are their 
dominant characteristics. For both, I will I) describe the 
methodology and illustrate it with an example; 2) discuss 
some of the methodologic problems that exist, emphasizing 
those for which future research may be most productive; and 
3) comment on problems of dissemination and implementa- 
tion, which I regard as a vital area for methodologic research 
in policy modeling. 
Economic Evaluation Models 
Cost-effectiveness, cost-utility and cost-benefit analyses. 
Cost-effectiveness analysis is a method of economic evalu- 
ation, whose purpose is to assess the relative efficiency with 
which a medical procedure or health program uses resources 
to produce a desired health output (1). If the objective of the 
decision maker is to maximize some measure of health 
benefit subject to a constraint on available resources or 
expenditures, then the cost-effectiveness ratio: 
Net resource cost (C)/Net health effectiveness (E), 
becomes a suitable yardstick for ranking competing pro- 
grams or health practices that both consume resources and 
produce benefits. 
Net resource costs consist of the costs of the procedure 
or program intervention itself, plus induced costs of tests 
and treatments added (such as coronary angiograms induced 
by abnormal exercise electrocardiograms [ECGs] or repeat 
exercise ECG under the same circumstances), less induced 
savings for tests and treatments averted, plus costs of 
treating side effects and complications, less costs of treating 
morbid events averted as a result of treatment (such as 
stroke averted by antihypertensive therapy), plus costs of 
treating morbidity occurring in the years of life added by 
successful treatment. These costs, measured in dollars, are 
ideally measured as true resource costs, rather than prices, 
to the extent that the two diverge. 
Net health efectiveness, the denominator of the cost- 
effectiveness ratio, can sometimes be measured adequately 
in units of increased life expectancy. However, if quality of 
life is an important attribute of desired outcome, as is often 
the case in the management of cardiovascular conditions 
such as chest pain, then measures that incorporate quality of 
life are desirable. Quality-adjusted life expectancy is such a 
measure. Each year of life is weighted by a value on a scale 
of 0 to I corresponding to the relative quality of that year, 
where 1 represents good health and 0 represents a health 
state as severe as death. Because these weights are ulti- 
mately subjective value judgments, reflecting the prefer- 
ences (or utilities) of the target population as perceived by 
the decisionmaker, this version of cost-effectiveness analy- 
sis is sometimes referred to as “cost-utility analysis” and the 
ratio as a “cost-utility ratio” (2). 
Cost-benejit analysis seeks to assign a monetary value to 
health care benefits, in contrast to cost-effectiveness and 
cost-utility analyses, which limit monetization to the inputs 
to health care. Thus, in cost-benefit analysis a year of life 
gained would be assigned a dollar value, based on the 
economic value of that person-year in the economy or based 
on measures of willingness to pay for increased longevity as 
obtained from econometric studies or surveys (2). Instead of 
a ratio of dollars per unit of health effectiveness, cost-benefit 
analysis produces a measure of net economic benefit for 
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each health program evaluated. Because the process of 
assigning economic value to human life and health is contro- 
versial, and in most resource allocation contexts unneces- 
sary, I regard cost-effectiveness (and its variant cost-utility) 
analysis as the more practical and acceptable economic 
evaluation model and will, therefore, address my remarks to 
it. 
Cost-effectiveness analysis of diagnosis and treatment of 
patients with chest pain. In an application of cost-ef- 
fectiveness analysis to the choice between medical manage- 
ment and coronary artery bypass graft surgery for patients 
with chest pain (3), data from published medical reports 
were used to obtain estimates of operative mortality and 
long-term survival rates and probabilities of symptom relief 
or improvement. Costs were based on available charge data 
(recognizing the limitations), and the quality of life weights 
were assigned by the authors to represent a range of sever- 
ity. Results suggest that surgery is most cost-effective for 
patients with left main and three vessel coronary artery 
disease and for one and two vessel coronary artery disease 
only if accompanied by severe pain. The threshold value of 
the cost-effectiveness ratio, above which it would be judged 
that resources are best spent in other areas. would depend 
on analogous cost-effectiveness ratios for competing pro- 
grams. 
A subsequent analysis (4) extended the previous one to 
include the prior decision of whether to elect exercise ECG 
or angiography in patients with varying types and degrees of 
chest pain and with varying a priori probabilities of having 
operable coronary artery disease. Among the conclusions 
from this analysis were that patients with typical angina 
should undergo angiography directly (provided that one is 
willing and able to pay at least $15,000 to gain a quality- 
adjusted year of life), that patients with nonspecific chest 
pain should undergo exercise ECG before angiography and 
that the decision for patients with atypical angina depends 
importantly on risk factors, severity of pain and the cost- 
effectiveness threshold. 
Both of these analyses were performed before publication 
of data from the Coronary Artery Surgery Study, and neither 
considered coronary angioplasty as a treatment option. This 
observation serves to highlight the need to keep cost- 
effectiveness analyses current with published data and new 
technologies, and for users of these models to recognize that 
conclusions may change as new evidence arises. 
Cost-effectiveness and cost-benefit analyses performed 
within the domain of coronary heart disease have been 
reviewed recently (51, so I will not attempt such a review 
here. 
Problems of methodology. Methodologic problems 
toward which future research can contribute insights if not 
solutions include outcome measurement, cost finding and 
time discounting. 
Outcome measuwment. Defining a suitable measure of 
health effectiveness, or utility, has been a problem from the 
time of the earliest efforts at cost-effectiveness analysis. The 
method of quality-adjusted life-years has been advanced 
considerably (6). and although some analysts use state of the 
art utility assessment methods to assign quality weights for a 
target population, others continue to use arbitrary weights 
and rely on sensitivity analysis to explore the effects of the 
weights. Standardized sets of weights based on population 
surveys do exist (71, but the health states tend to overrepre- 
sent the most disabling end of the spectrum, and the weights 
themselves are based on category scaling, which has limited 
usefulness in prescriptive analyses. Perhaps a new round of 
survey research, concentrating on the health states most 
relevant to cardiovascular disease, would provide a valuable 
data base for cost-effectiveness analyses. 
Costfinding. Until recently, cost finding has been largely 
a matter of using charges and asserting that, on average, 
charges approximate costs in a cost-based reimbursement 
system. Now, the reimbursement system is not predomi- 
nantly cost-based. Concomitantly, hospitals and even some 
physician groups are adopting newly developed cost- 
accounting systems that enable them to uncover the true 
costs of clinical practices. Although these systems are not 
yet widely disseminated and are often more directed toward 
assigning responsibility for profit and loss than toward cost 
finding, they hold promise for revealing important data for 
policy analysis. 
Time discounting. The controversy about discounting the 
future health benefits has been largely resolved, at least 
among methodologists, although many critics remain dis- 
turbed by the implications, which include adverse effects on 
cost-effectiveness ratios for preventive measures. One meth- 
odologic aspect that has not been resolved is how to recon- 
cile the societal rationale for discounting the future (re- 
sources spent today rather than invested could have yielded 
even more resources for future life-saving activities) and the 
well documented fact that individuals value future years less 
than current ones. The problem arises because the rate at 
which individuals discount their own healthy future is gen- 
erally not the same as the societal rate of discount, and may 
not even be a constant rate over time. In cardiovascular 
disease, choices between prevention and early treatment are 
particularly sensitive to discounting procedures in cost- 
effectiveness analyses (8). 
Problems of communication and implementation related to 
cost-effectiveness analysis. Problems related to ranking and 
grouping of programs and patients. The purpose of cost- 
effectiveness analysis is to provide a relative ranking of 
programs such that decisionmakers who influence the allo- 
cation of limited resources can use this information along 
with other clinical, ethical and political considerations to set 
priorities. Such a set of comparisons across treatment and 
prevention programs can be both illuminating, intimidating 
and more than a little distasteful to some potential users (5). 
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Users of these analyses need to understand the context of 
limited resources in which these analyses are relevant. The 
point is not that we would not like to be able to spend 
$lOO,OOO or $1 million to save each year of life by treating 
every patient who could benefit from a procedure. The point 
is that, if we do so for some procedures, there will not be 
enough resources to save even more lives for the same 
amount of money by other means. There are choices at the 
aggregate level, even if clinicians, quite appropriately, are 
reluctant to consider them while at the individual patient’s 
bedside. 
One prevalent source of resistance in cost-effectiveness 
analysis is the need to aggregate categories of patients; the 
“standard” patient in an analysis usually resembles no 
patient in particular, so it is easy to point out the exceptions 
and special cases. Nonetheless, general guidelines for re- 
source allocation can be formulated, with exceptions permit- 
ted at the bedside as long as the aggregate effect of the 
exceptions in both directions balances out in the end. 
Otherwise, the inefficiencies in delivering the health benefits 
just described are bound to occur, with some decidedly more 
cost-effective programs squeezed out. 
Timing of cost-benefit analyses. One implementation 
issue on which there is some disagreement is when is the 
appropriate time to engage in cost-effectiveness analysis 
during the life of an emerging technology. Intravenous and 
intracoronary thrombolysis make a case in point. I firmly 
believe that it is never too early to begin a cost-effectiveness 
analysis, provided that the analysis is updated reasonably 
often as new and scientifically more reliable data become 
available. Technologies that have the potential to be ex- 
tremely cost-effective should be given a higher priority-put 
on a faster track for evaluation and adoption-than those 
with a more limited potential to improve health at an 
affordable cost. Early cost-effectiveness analysis can be 
useful in bounding the potential value of a technology in an 
environment of limited resources, and this knowledge can be 
useful not only to the National Institutes of Health, but also 
to the clinicians and managers of the research hospitals that 
pioneer the use of these technologies. 
Diflerence between perspectives qf society nnd those Of 
health care providers. The most important obstacle to effec- 
tive use of cost-effectiveness models is that they usually 
adopt the societal perspective exclusively, ignoring (or only 
paying lip service) to the perspectives of real decisionmakers 
who can use cost-effectiveness information in their own 
organizations. The rapid growth of managed care portends 
an increasing interest among such managers of care in 
optimizing the use of patient care dollars across the range of 
potential interventions that can be applied to the manage- 
ment of the patient’s cardiovascular disease. Tradeoffs be- 
tween dollars on prevention and dollars on acute care are 
crucial to the task of a case manager who needs to balance a 
budget as well as do the best for the patient. I regard the case 
managers of the future as potentially important users of 
cost-effectiveness analyses, provided that the analyses rec- 
ognize that perspective to the extent that it diverges from the 
societal perspective. Indeed, the degree to which cost- 
effective care for society differs from cost-effective care for 
health care delivery organizations is a measure of the need to 
alter the incentives to providers to approach as closely as 
possible the interests of the population that both pays for and 
benefits from health care. 
Large-Scale Forecasting Models 
After a number of cost-effectiveness analyses of interven- 
tions in cardiovascular disease had been performed, it be- 
came clear that the costs and benefits of one intervention 
depended on the assumptions made about the costs and 
efficacy of other interventions. For example, the value and 
net cost of preventing myocardial infarction by lowering 
blood pressure depend on the costs and consequences of 
treating myocardial infarction. (As a fanciful limiting case to 
illustrate the point, how cost-effective would antihyperten- 
sive treatment be if stroke and myocardial infarction could 
be cured without residual effects at very low cost?) To 
recognize this interaction among programs, my colleagues 
and 1 developed a pilot model that can be used to simulate 
the combined effects of existing and future interventions. As 
a population-based model, it can also be used, as we have 
done to date, to project current epidemiologic facts and 
clinical practices into the future to forecast the mortality, 
morbidity and cost associated with coronary heart disease in 
the U.S. population and to explore the implications of 
changes in preventive and therapeutic practices (9). 
Coronary heart disease policy model. Our coronary heart 
disease policy model is a compartmental, state-transition 
model consisting of three sectors: a demographic- 
epidemiologic model that includes 35 to 84 year old persons 
free of coronary heart disease and generates new cases 
annually, as well as deaths from other causes; a bridge 
model that assigns new cases according to the initial coro- 
nary heart disease event and generates fatalities from initial 
events; and a disease history model that follows subsequent 
coronary heart disease events and both coronary heart 
disease-related and other fatalities up to age 85 years. Costs 
are generated by all three submodels and include costs of 
preventive, diagnostic and therapeutic interventions. The 
states of the demographic-epidemiologic model correspond 
to gender, age and each of four risk factors: diastolic blood 
pressure, serum cholesterol, smoking status and relative 
weight. The states of the disease history model describe 
previous coronary heart disease events, including cardiac 
arrest, myocardial infarction and coronary bypass surgery. 
Transition probabilities throughout the model were based on 
published clinical data and public health statistics. 
To date, we have used the model to project the incidence 
42A WEINSTEIN JACC Vol. 14. No. 3 
POLICY MODELING FOR CARDIOVASCULAR DISEASE September 1989:38AA3A 
of coronary heart disease, mortality rates and costs under 
the assumption that current cohort-specific risk factor dis- 
tributions will remain unchanged, subject only to historic 
changes with age, and that current treatment efficacies and 
costs will persist. The model projects a 40% to 50% increase 
in the number of incident cases, coronary heart disease 
deaths and coronary heart disease costs by the year 2010, 
largely because of the aging of the baby boom cohort. 
Unprecedented risk factor modifications not yet observed in 
epidemiologic surveys would be required to offset these 
demographic forces. We have just begun to explore the 
effects of specific risk factor interventions. both targeted and 
population-wide, and are planning to use the model to assess 
the consequences of widespread adoption of newly validated 
treatment technologies. 
Methodologic problems. Model size and complexity. The 
biggest single methodologic problem we have faced in large- 
scale modeling is dimensionahty. Constraints on computing 
time and costs forced us to restrict the number of risk factors 
and disease history states, and to make numerous indepen- 
dence assumptions. We are currently struggling with the 
issue of how to incorporate coronary angioplasty into the 
model without doubling the size of the disease history 
model. In the end, the published clinical data rarely provide 
transition probabilities by meticulously defined history 
strata, so that problem may be one more of face validity of 
the model than limits on the ability to incorporate the best 
available data. One should not minimize the importance of 
face validity, however; although some critics abhor the use 
of subjective estimates in models, others reject models that 
fail to incorporate their own beliefs, however poorly sub- 
stantiated by scientific evidence. Research on optimal model 
size and complexity would certainly be welcome. The ques- 
tion has even been posed as to whether our model is too 
complex already; perhaps a simple time series approach 
(that is, extrapolate the past to the future) would yield 
equally credible forecasts. This question, however, does not 
address our other objective, namely, to evaluate the policy 
consequences of new interventions or new applications of 
existing ones. 
Flexibility. Another problem is that our model is not 
particularly flexible. Programmed in a relatively low level 
computer language by modern standards (Fortran), struc- 
tural changes in the mode1 such as adding new states for 
angioplasty require reprogramming. Higher level modeling 
languages (such as DYNAMO) have their place, but are not 
adaptable to the particular requirements of our model. 
Development of modeling languages oriented toward the 
goals of disease policy modeling may be a spinoff of this line 
of research. 
Static versus dynamic capability. A third methodologic 
problem is that our mode1 is already too complex to consider 
diagnostic tests dynamically. Our coronary heart disease 
policy mode1 regards diagnostic tests as static contributors 
to utilization and efficacy rates of treatments as well as costs. 
Changes in diagnostic efficacy can be reflected only indi- 
rectly by altering the aggregate effectiveness of treatments 
that might improve because the treatments can be targeted at 
the patients who stand to benefit the most. 
Problems in establishing vakdity. Finally, there is the 
question of how to establish the validity of a forecasting 
model. If the assumptions seem reasonable, but future 
events fail to confirm the predictions, is the model at fault or 
were the events that caused the differences unforeseeable or 
at least improvable at the time the mode1 was used? We may 
not be able to check each and every assumption that was 
built into the model, only their aggregate effects. Therefore, 
I would attach as much weight to face validity of the model, 
and its ability to reflect available evidence at the time, as to 
its ability to predict the future in any given trial. On the other 
hand, we need an independent test of the validity of simpli- 
fications and assumptions made, and therein lies that meth- 
odologic problem. 
The associated problem in communicating these models 
to users is to stress that their predictions are only as good 
as the assumptions, and may be worse if the unforeseen 
or improbable happens. Economic forecasters are riding 
through hard times because of misunderstanding of this 
issue. Users must understand that the best forecasting model 
may not be the one that makes the most accurate forecast. 
Potential users. Who are the users of such policy models? 
The National Heart, Lung, and Blood Institute is one 
potential user in setting research priorities based on future 
needs. Their partners in the private sector, the pharmaceu- 
tical and medical device industries, can also benefit from 
forecasts of future demands. Health care delivery organiza- 
tions, in their strategic planning, need predictions not only of 
future demand for care, but also of what combination of 
interventions are most cost-effective over the life history of 
a disease. The latter information from policy models can be 
valuable in defining service packages and prices for case 
management of coronary heart disease from various stages 
until death or successful resolution. 
Conclusions. Rapid progress was made during the 1970s 
and early 1980s in both the methodology and application of 
policy modeling for decision making in cardiovascular dis- 
ease. We are now in a period of consolidation and imple- 
mentation. Analysts must turn outward to serve the needs of 
particular decisionmakers. They must further contribute to 
the debate about how the health care sector should be 
structured so as to be able to make use of t,he information 
policy models can provide. 
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